Botulinum toxin A in the treatment of infantile cerebral palsy. Taking into account multilevel, integrated treatment;Botulinumtoxin A bei der behandlung der infantilen zerebralparese: Unter besonderer berücksichtigung der mehretagen- und kombinationsbehandlung

Orthopade

Volumn 33, Issue 10, 2004, Pages 1119-1128

  Molenaers, G ^a   Desloovere, K ^a   De Cat, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Botulinum toxin A treatment; Cerebral palsy; Integrated approach; Multilevel treatment; Plaster treatment

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

CEREBRAL PALSY; DRUG EFFICACY; HUMAN; NEUROMUSCULAR BLOCKING; ORTHOSIS; PHYSIOTHERAPY; PLASTER CAST; REVIEW; SPASTICITY; TREATMENT PLANNING; ADULT; ANIMAL; ARTICLE; CHILD; COMPARATIVE STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; KINESIOTHERAPY; MULTIMODALITY CANCER THERAPY; ORTHOTICS; TIME; TREATMENT OUTCOME;

ADULT; ANIMALS; BOTULINUM TOXIN TYPE A; CASTS, SURGICAL; CEREBRAL PALSY; CHILD; COMBINED MODALITY THERAPY; EXERCISE THERAPY; HUMANS; INJECTIONS, INTRAMUSCULAR; NEUROMUSCULAR AGENTS; ORTHOTIC DEVICES; TIME FACTORS; TREATMENT OUTCOME;

EID: 6344240786     PISSN: 00854530     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00132-004-0688-2     Document Type: Review

References (50)

1. Aoki RK, Ismail M, Tang-Liu D, Brar B, Wheeler LA (1997) Botulinum toxin type A: from toxin to therapeutic agent, Eur J Neurol 4: 51-53
2. Aoki KR (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacoloical actions. Eur J Neurol 8: 21-19
3. Awaad Y et al. (1999) Treatment of childhood myoclonus with botulinum toxin type A. J Child Neurol 14: 781-786
4. Awaad Y et al. (2000) High dose of botulinum toxin type-A (BTX): safety and efficacy in patients with cerebral palsy. Mov Disord 15 (suppl 3): 137
5. Baker R (2000) Botulinum toxin A for treatment of dynamic equinus spasticity associated with cerebral palsy: results of double-blind placebo controlled dose-ranging study. Dev Med Child Neurol 42 (suppl 84): 10
6. Berger W (1998) Characteristics of locomotor control in children with cerebral palsy. Neuroscience and Biobehavioral Reviews 22 (4): 579-582
7. Bleck EB (1987) Orthopaedic management in cerebral palsy, Mac Keith Press, London, pp 142-212
8. Borton D, Walker K, Nattrass G, Graham HK (1998) Calf lengthening in Cerebral Palsy - Risk factor outcome analysis, AACPDM San Antonio. Dev Med Child Neurol 40 (suppl)
9. Boyd R, Graham HK (1997) Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 4: 515-522
10. Boyd RN, Starr R, Wolfe R, Graham HK (2000) Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral Palsy, Dev Med Child Neurol 42: 32-41
11. Boyd RN, Hays RM (2001) Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 8: 1-20
12. Boyd RN, Morris ME, Graham HK (2001) Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol 8 (suppl 5): 150-166
13. Chell J, Hunter JB (2001) Uninary incontinence following botulinum toxin A injection in cerebral palsy, Abstract of the 20° EPOS meeting, Montpellier, France (April 4-7)
14. Corry I, Cosgrove A, Duffy C, McNeil S, Taylor T, Graham H (1998) Botulinum toxin A compared with stretching casts in the treatment of spastic equinus, a randomised prospective trial. J Pediatr Orthop 18: 304-311
15. Coleman GJ, King JA, Reddihough DS (1995) A pilot evaluation of conductive education based intervention for children with cerebral palsy: the Tongala project. J Pediatric Child Health 31: 412-417
16. Cosgrove AP, Corry IS, Graham HK (1994) Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 36: 386-396
17. Damiano DL, Quinlivan J, Owen BF, Shaffrey M, Abel MF (2001) Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function. Eur J Neurol 8 (suppl 5): 40-49
18. Desloovere K, Molenaers G, Jonkers I, Van Deun S, Nijs J (2000) The effect of combined botulinum toxin injections and serial casting on gait disorders in cerebral palsy. Gait Posture 12: 57
19. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, Eyssen M, Pauwels P, De Cock P (2001) A randomised study of botulinum toxin A & casting in the ambulant child with cerebral palsy using objective measures. Eur J Neurol 8 (suppl 5): 75-87
20. Fabry G, Liu XC, Molenaers G (1999) Gait patterns in patients with spastic diplegic cerebral palsy who underwent staged operations. J Pediatr Orthop 8: 33-38
21. Fetters L, Kluisick J (1996) The effect of neurodevelopmental treatment versus practice on the reaching of children with spastic cerebral palsy. Phys Ther 76: 346-358
22. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK (1999) Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 35: 71-77
23. Gage JR (1991) Gait Analysis in Cerebral Palsy. Mac Keith Press, London, pp 101-131
24. Goldstein EM (2001) Spasticity management: an overview. J Child Neurol 16: 16-23
25. Goldstein M, Harper DC (2001) Management of cerebral palsy: equinus gait. Dev Med Child Neurol 43: 563-569
26. Graham HK, Aoki KR, Autti-Rämo I et al. (2000) Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 11: 67-79
27. Hesse S, Reiter F, Konrad M, Jahnke MT (1998) Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor Spasticity after stroke: a randomized, double-blind, placebo controlled trial. Clin Rehabil 12: 381-388
28. Koman LA et al. (2001) Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108: 1062-1071
29. Law M, Russell D, Pollock N, Rosenbaum P, Walter S, King G (1997) A comparison of intensive neurodevelopmental therapy plus casting and a regular occupational therapy program for children with cerebral palsy. Dev Med Child Neurol 39: 664-670
30. Leach J (1997) Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve 1997 (suppl 6): 5194-5207
31. Leonard CT, Hirschfeld H, Forssberg H (1991) The development of independent walking in children with cerebral palsy. Dev Med Child Neurol 33: 567-577
32. Misiaszek JE, Pearson KG (2002) Adaptive changes in locomotor activity following botulinum toxin injection in ankle extensor muscles of cats. J Neurophysiol 87: 229-239
33. Molenaers G, Desloovere K, Eyssen M, De Cat J, Jonkers I, P De Cock (1999) Botulinum toxin type A treatment of cerebral palsy; an integrated approach. Eur J Neurol 6 (suppl 4): 551-557
34. Molenaers G, Desloovere K, Jonkers I, Glorieux F, De Cock P (1999) The effect of multilevel botulinum toxin type A treatment combined with short leg casting and othotic management on the gait of CP children. Gait and posture 10: 74
35. Molenaers G, Eyssen M, Desloovere K, Jonkers I, De Cock P (1999) A multilevel approach to botulinum toxin type A treatment of the (ilio)psoas in spasticity in cerebral palsy. Eur J Neurol 6 (suppl 4): 559-562
36. Okamoto T, Okamoto K (2001) Electromyographic characteristics at the onset of independent walking in infancy. Electromyographic and Clinical Neurophysiology 41: 33-41
37. Ong HT, Chong HN, Yap SSP (2001) Comprehensive management of spasticity in cerebral palsy: Role of physical therapy and other adjunctive treatments. Singapore Pediatr J 43: 133-136
38. Polak F, Morton R, Ward C, Wallace WA, Döderlein L, Siebel A (2002) Double-blind comparison study of two doses of botulinum toxin A injected into the calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 44: 551-555
39. Rang M, Silver R, de la Garza J (1986) Cerebral palsy. In: Lovell WW, Winter RB (eds) Paediatric orthopaedics (2nd edn) Lippincott, Philadelphia, pp 345-396
40. Reddihough DS, King J, Coleman G, Catanese T (1998) Efficacy of programs based on conductive education for young children with cerebral palsy. Dev Med Child Neurol 40: 763-770
41. Renshaw T, Green NE, Griffin PP, Root L (1995) Cerebral Palsy: Orthopedic management. J Bone Joint Surg 77: 1590-1606
42. Sanders I, Shaari C, Amirali LAY (1999) The glycogen depletion assay and the measurement of botulinum toxin injections. Abstract from International Conference on basic and therapeutic aspects of botulinum and tetanus toxins, Orlando/FL, Nov 16-18 1999 (p 33)
43. Smedal T, Gjelsvik B, Lygren H, Bergmann R, Waje-Andreassen U, Gronning M (2001) Botulinum toxin A and effect on spasticity. Tidsskr Nor Laegeforen 121: 3277-3280
44. Suliman IA, Lindgren JU, Gillberg PG, Diab KM, Adem A (1997) Effect of immobilization on skeletal muscle nicotinic cholinergic receptors in the rat. Neuroreport 8: 2821-2824
45. Suputtitada A (2000) Managing spasticity in pediatric cerebral palsy using very low dose of botulinum toxin type A: preliminary report, Am J Phys Med Rehabil 79: 320-326
46. Sutherland DH, Santi M, Abel MF (1990) Treatment of stiff-knee gait in cerebral palsy: a comparison by gait analysis of distal rectus femoris transfer versus proximal rectus release. J Pediatr Orthop 10: 433-441
47. Terence ES (2001) Clinical utility of botulinum toxin in the treatment of cerebral palsy; comprehensive review. J Child Neurol 16: 37-46
48. Wenger DR, Rang M (1993) The art and practice of children's orthopaedics, Raven, New York
49. Willenborg MJ, Shut JS, Smith BP, Estrada RL, Castle JA, Koman LA (2002) Technique for iliopsoas ultrasound-guided active electromyography-directed botulinum A toxin injection in cerebral palsy. J Pediatr Orthop 22: 165-168
50. Zurcher AW, Molenaers G, Fabry G (1999) Treatment of equinus in young children with hemiplegic cerebral palsy: recurrence after achilles tendon lengthening and kinematic and kinetic evaluation of treatment with botulinum toxin. Gait Posture 10: 90